Inotuzumab ozogamicin (INO) in combination with mini-hyper-CVD as frontline therapy for older patients (≥60 years) with acute lymphoblastic leukemia (ALL)
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Koji Sasaki, Hagop Kantarjian, Susan O'Brien, Deborah Thomas, Guillermo Garcia-Manero, Farhad Ravandi, Jenny Dahl, Nitin Jain, Marina Konopleva, Jovitta Jacob, Rebecca Garris, Jorge Cortes, Elias Jabbour (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

Inotuzumab ozogamicin in combination with mini-hyper-CVD as salvage therapy for patients with relapsed/refractory acute lymphoblastic leukemia
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Koji Sasaki, Hagop Kantarjian, Susan O’Brien, Deborah Thomas, Farhad Ravandi, Guillermo Garcia-Manero, Tapan Kadia, Nitin Jain, Marina Konopleva, Zeev Estrov, Koichi Takahashi, Maria Khouri, Jovitta Jacob, Rebecca Garris, Jorge Cortes, Elias Jabbour (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

Phase II study of hyper-CMAD with liposomal vincristine as frontline therapy for patients with acute lymphoblastic leukemia
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Koji Sasaki, Susan O’Brien, Deborah Thomas, Maria Khouri, Musa Yilmaz, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur, Rebecca Garris, Evguenia Gachimova, Courtney Dinardo, Naveen Pemmaraju, Jorge Cortes, Hagop Kantarjian, Elias Jabbour (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL)
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Koji Sasaki, Susan O’Brien, Farhad Ravandi, Deborah Thomas, Haim G. Moore, Jorge Cortes, Naveen Pemmaraju, Musa Yilmaz, Tapan Kadia, Rebecca Garris, Guillermo Garcia-Manero, Vicky Jeanis, Gautam Borthakur, William Wierda, Alessandra Ferrajoli, Hagop Kantarjian, Elias Jabbour (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

Ofatumumab in Combination with Hyper-CVAD Regimen as Frontline Treatment for Adults with CD-20 Positive Acute Lymphocytic Leukemia
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Koji Sasaki, Musa Yilmaz, Hagop Kantarjian, Deborah Thomas, Maria Khouri, Guillermo Garcia-Manero, Rebecca Garris, Jorge Cortes, Heather Schroeder, Tapan Kadia, Farhad Ravandi, Srdan Verstovsek, Naval Daver, Nitin Jain, Marina Konopleva, Susan O’Brien, Elias Jabbour (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

Targeting of JAK-STAT signaling pathway and BCL-2 family proteins in Ph-like acute lymphoblastic leukemia
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Gevorg Tamamyan, Ce Shi, Kathryn Roberts, Helen Ma, Charles Mullighan, Marina Konopleva (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

Hepatic iron overload (HIO) is strongly correlated with serum ferritin levels and inferior survival in patients that underwent allogeneic hematopoietic stem cell transplantation (alloHSCT)
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Serdar Sivgin, Suleyman Baldane, Kemal Deniz, Gokmen Zararsiz, Leylagul Kaynar, Mustafa Cetin, Ali Unal, Bulent Eser (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

Cytogenetics of Adult Hispanic ALL Patients at Los Angeles County Hospital and Keck Hospital
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Zunera Ghaznavi, Golnaz Vahdani, Wendy Hsiao, Mojtaba Akhtari (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

Survival trends in Adult Acute Lymphoblastic Leukemia Patients at Los Angeles County Hospital and Keck Hospital
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Golnaz Vahdani, Zunera Ghaznavi, Wendy Hsiao, Mojtaba Akhtari (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

Bilateral Cranial Nerve Palsy as a Harbinger of Acute Lymphoblastic Leukemia
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Shiraj Sen, Arjun Gupta, Rigoberto Ramirez, Harris Naina (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

Incidence trend of the leukemia reported cases in the kingdom of Saudi Arabia, observational descriptive statistic from Saudi Cancer Registry
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Rashed B. Albakr (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

CXCR4 Chemokine Receptor as a therapeutic target in B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Shubhchintan Randhawa, Byung Sik Cho, Dipanjan Ghosh, Amnon Peled, Richard E. Davis, Marina Konopleva, Jan A. Burger (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

Immunophenotypic Characterization of Cytogenetic subgroups in Egyptian Pediatric B-Acute Lymphoblastic Leukemia Patients
Publication date: September 2015 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 15, Supplement 2 Author(s): Shady Awad, Mahmoud M. Kamel, Mahmoud A. Ayoub, Ahmed M. Kamel, Essam Elnoshokaty, Niveen El Hifnawi (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2015 Category: Cancer & Oncology Source Type: research

Adverse Events during Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product
Conclusion Adverse events are common during stem cell infusion, and generally cardiopulmonary. Teaser Stem cell transplantation is a treatment option for patients with various malignancies. However, there may be a risk of adverse events in the peri-transplant period associated with the infusion itself. We studied adverse events in 460 patients undergoing transplantation at Northwestern University Robert H. Lurie Comprehensive Cancer Center. 56.7% of patients experienced adverse events, which were generally cardiopulmonary in nature. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 3, 2015 Category: Cancer & Oncology Source Type: research

Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and Opportunities
Publication date: Available online 2 September 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Stuart L. Goldberg In clinical trials, where treatment algorithms and monitoring schedules are tightly prescribed by research protocols, outcomes for patients with chronic myeloid leukemia (CML) have been excellent with >90% 5-year survival rates. However, outside clinical trials, in the so-called “real world”, monitoring schedules are more variable, with less than 40% of patients undergoing quantitative PCR molecular testing 3-4 times during the first year following diagnosis as recommended by...
Source: Clinical Lymphoma Myeloma and Leukemia - September 3, 2015 Category: Cancer & Oncology Source Type: research

Lenalidomide Treatment for lower risk non-deletion 5q Myelodysplastic syndromes Patients Yields higher Response Rates when Used Prior to Azanucleosides
Conclusions Lenalidomide appears to yield a higher HI-E rate in non-del5q LR-MDS when used as first-line therapy after ESAs failure. If validated in larger cohorts, lenalidomide rather than azacitidine should be considered for first-line therapy after ESAs failure. Teaser In patients with lower-risk myelodysplastic syndromes (LR-MDS) in whom erythropoiesis-stimulating agents (ESAs) fail, optimal sequencing of lenalidomide and azanucleosides is unknown. In a retrospective analysis of patients who received both azacitidine and lenalidomide, erythroid hematologic improvement rate was 38% vs. 12% when lenalidomide was used as ...
Source: Clinical Lymphoma Myeloma and Leukemia - September 3, 2015 Category: Cancer & Oncology Source Type: research

Essential Thrombocythemia: The Dermatological Point of View
Publication date: Available online 3 September 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Emanuele Cozzani, Alessandra Iurlo, Giulia Merlo, Daniele Cattaneo, Martina Burlando, Ivana Pierri, Luigi Gugliotta, Aurora Parodi Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an increase of the blood platelets and dominated by a predisposition to vascular events. Cutaneous manifestations may complicate its course. In particular, itching is the most common symptom complained, however, it is reported in different percentages ranging from 3% to 46% depending on the availab...
Source: Clinical Lymphoma Myeloma and Leukemia - September 3, 2015 Category: Cancer & Oncology Source Type: research

A phase 2 trial of fludarabine / melphalan 100 conditioning therapy followed by allogeneic hematopoietic cell transplantation for patients with lymphoma
Conclusion Conditioning therapy with a lower dose of melphalan in combination with fludarabine appears to be promising in allogeneic HCT for lymphoma. This study was registered at www.Clinicaltrials.gov as #NCT00772811. Graphical abstract (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 3, 2015 Category: Cancer & Oncology Source Type: research

The role of β-catenin in bcr/abl negative myeloproliferative neoplasms: an immunohistochemical study
Conclusions This study suggests that Wnt/ β-catenin signaling pathway has a role in the angiogenesis of PMF and in the thrombopoiesis of PV and ET. Hence, targeting Wnt/ β-catenin signaling pathway could open new avenues for novel therapeutic approaches in bcr/abl negative myeloproliferative neoplasms. Teaser The dysregulation of Wnt/ β-catenin signaling pathway causes to various diseases. In this study we aimed to reveal the role of β-catenin in bcr/abl nagative MPN. The expression of β-catenin was examined in bone marrow with immunohistochemical method in 66 patients and in 30 controls. The resul...
Source: Clinical Lymphoma Myeloma and Leukemia - September 3, 2015 Category: Cancer & Oncology Source Type: research

Importance of Histologic Verification of Positive Positron Emission Tomography/Computed Tomography Findings in the Follow-Up of Patients With Malignant Lymphoma
Conclusion This study emphasizes that the histologic diagnosis should be confirmed in posttherapy PET/CT-positive patients via biopsy before adjusting the treatment regimen as a result of the high false-positive rate, including unexpected SPM or benign/normal tissue lesions. Micro-Abstract We evaluated histologically verified after therapy positron emission tomography/computed tomography (PET/CT)-positive lesions in the follow-up of 190 patients with malignant lymphoma in first complete remission. Among 32 patients with histologically verified disease, 10 exhibited relapse of lymphoma, 11 had second primary malignancies, ...
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2015 Category: Cancer & Oncology Source Type: research

Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma
Conclusion In our experience, the incidence of recognized LON is low (6%), although its real incidence may be greater because of the asymptomatic course and quick recovery in most cases. Infectious complications are unusual, but life-threatening complications can emerge. A careful evaluation of all cases of LON is warranted. Micro-Abstract The incidence of late-onset neutropenia resulting from rituximab among 183 patients with non-Hodgkin lymphoma was 6% (13 episodes in 11 patients). The median time to onset of neutropenia was 75 days, and the median duration was 100 days. Although infectious complications were uncommon, ...
Source: Clinical Lymphoma Myeloma and Leukemia - August 29, 2015 Category: Cancer & Oncology Source Type: research

Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma
Conclusion GM–CSF-based chemoimmunotherapy was well-tolerated and resulted in a high response rate and warrants evaluation in larger studies. Micro-Abstract Granulocyte-monocyte colony stimulating factor (GM-CSF) has immunomodulatory activity and might enhance antitumor immunity when combined with chemotherapy. We evaluated GM-CSF in combination with chemoimmunotherapy for a maximum of 6 cycles. The overall response rate for all patients was 87%, and there were no toxic deaths during the study. This therapy was well-tolerated and contributed to a high response rate. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 19, 2015 Category: Cancer & Oncology Source Type: research

Circulating Levels of Urokinase-Type Plasminogen Activator Receptor (uPAR) and D-Dimer in Patients with Hematological Malignancies
Conclusions We found differences in D-Dimer serum levels and soluble uPAR between controls and patients with lymphoma. These results should be considered as a biomarkers of response and survival in patients with lymphoma. Teaser This study aims to estimate sera levels of uPAR and D-D as fibrinolysis markers and to determine their association with outcome. We found an increased frequency of positive D-D. Highest sera levels of both D-D and soluble uPAR were detects for lymphoma patients against controls. These biomarkers should be related in our population with treatment response and survival. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 15, 2015 Category: Cancer & Oncology Source Type: research

Patterns of Venous Thromboembolism Prophylaxis during Treatment of Acute Leukemia: Results of a North-American Web-Based Survey
Publication date: Available online 6 August 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Eun-Ju Lee, B. Douglas Smith, Jessica W. Merrey, Alfred I. Lee, Nikolai A. Podoltsev, Lisa Barbarotta, Mark R. Litzow, Thomas Prebet, Selina M. Luger, Steven Gore, Michael B. Streiff, Amer M. Zeidan Venous thromboembolism (VTE) occurs in 2-12% of patients with acute leukemia (AL) despite disease and therapy-associated thrombocytopenia, and can be associated with significant morbidity and mortality. Due to limited high-quality studies, there are no evidence-based guidelines for VTE prophylaxis in this pati...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2015 Category: Cancer & Oncology Source Type: research

Late-onset neutropenia following rituximab-containing therapy for non-Hodgkin lymphoma
Conclusions In our experience the incidence of recognized LON is low (6%) even though its real incidence may be greater because the asymptomatic course and quick recovery in most of cases. Infectious complications are unusual, but life-threatening complications can emerge. A careful evaluation of all cases of LON is warranted. Teaser The incidence of late-onset neutropenia secondary to rituximab among 183 patients with non-Hodgkin lymphoma was 6% (13 episodes in 11 patients). The median time to onset of neutropenia was 75 days and the median duration was 100 days. Although infectious complications were uncommon, the import...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2015 Category: Cancer & Oncology Source Type: research

Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms (MPN) Group
In this report, we assess the potential impact of the changing landscape of PV management on daily practice. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2015 Category: Cancer & Oncology Source Type: research

Novel therapies for chronic lymphocytic leukemia: a Canadian perspective
Publication date: Available online 5 August 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): C. Owen, S. Assouline, J. Kuruvilla, C. Uchida, C. Bellingham, L. Sehn Chronic lymphocytic leukemia (CLL) is the most common adult lymphoproliferative disorder in Western countries. The current standard of care for CLL is chemoimmunotherapy, typically with fludarabine, cyclophosphamide, plus rituximab (FCR). However, the majority of patients with CLL are elderly with comorbidities and are unable to tolerate FCR. In order to choose the best treatment for each individual patient, physicians must balance efficacy ...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

Systemic Mastocytosis: Clinical Update and Future Directions
Publication date: Available online 5 August 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Douglas Tremblay, Nicole Carreau, Marina Kremyanskaya, John Mascarenhas Systemic mastocytosis (SM) is defined as the accumulation of abnormal mast cells (MC) in one or more extracutaneous tissues. Symptoms are due to either MC activation or organ infiltration and vary depending on disease subtype. More benign forms of SM, such as indolent SM (ISM) have a life expectancy similar to the general population while more aggressive subtypes, such as mast cell leukemia (MCL), have a median survival measured on the order ...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients with Arsenic Trioxide and Retinoic Acid in the United States
Conclusion The ATO + ATRA regimen is highly cost-effective compared to ATRA + AraC + additional chemotherapy or ATRA + IDA in the treatment of newly diagnosed low to intermediate risk APL patients. Teaser A Markov cohort model was used to estimate the cost-effectiveness of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) when used in first-line acute promyelocytic leukemia (APL) treatment. Results indicated that the ATO + ATRA regimen is highly cost-effective compared to ATRA + cytarabine + additional chemotherapy or ATRA + idarubicin in the treatment of newly diagnosed low to intermediate risk APL patients. ...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

Collateral circulation secondary to obstruction due to a cardiac lymphoma of the right atrium
Publication date: Available online 5 August 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): V. Riccioli, G. Privitera, T. Luca, R. Passanisi, C. Loreto, G. Musumeci, S. Castorina (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia (CML)
Conclusions Total healthcare costs are higher for episodes of TKI treatment failure than those of ongoing treatment, largely due to costly medical (non-pharmacologic) services. Avoiding treatment failure via optimal CML management may reduce healthcare costs. Teaser To understand the economic burden of tyrosine kinase inhibitor (TKI) treatment failure in chronic myeloid leukemia (CML), episodes of TKI treatment failure (Failures) in the one-year post-initiation were matched to those without failure (Non-Failures). Failures had significantly higher health care resource use and costs. The high economic burden of TKI treatmen...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

A Phase II Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Conclusions Despite some evidence of efficacy in this setting, the primary endpoint for the study was not met. In the era of targeted agents that are well-tolerated, the combination of fludarabine and alemtuzumab should be used rarely for a select group of fit patients who are refractory to standard therapies. Teaser We evaluated alemtuzumab in combination with fludarabine for patients with relapsed CLL. Sixty patients were enrolled in this phase II study, and the complete response rate was 8.3% with an overall response rate of 28.3%. While many patients developed CMV reactivation, these episodes were manageable. This regi...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

Prognostic value of anemia and C-reactive protein levels in diffuse large B-cell lymphoma
Conclusion Pretreatment anemia, pretreatment CRP levels, and six-month posttreatment anemia are significantly associated with poor outcome, but were not proven to be of additional prognostic value to the current risk stratification index for DLBCL. Teaser This study aimed to determine the prognostic value of pretreatment anemia, pretreatment C-reactive protein (CRP) levels, and six-month posttreatment anemia in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Pretreatment anemia, elevated pretreatment CRP levels, and six-month posttreatment anemia were significantly associated with poor outcome, but wer...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia
Publication date: Available online 5 August 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Andrew W. Hahn, Omer Jamy, Sara Nunnery, George Yaghmour, Smith Giri, Ranjan Pathak, Mike G. Martin Early mortality (EM) is all too frequent during induction chemotherapy for acute myeloid leukemia (AML). Older patients shoulder an undue amount of this burden due to the inherent biology of their disease and increased co-morbidities. EM rates in academic centers have seen a sharp decline over the past twenty years; however, data from population-based registries show that EM rates for the general population have...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

CD38 Monoclonal Antibody Therapies for Multiple Myeloma
Publication date: Available online 5 August 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sandy W. Wong, Raymond L. Comenzo The goal of this review is to provide historical, recent pre-clinical and current clinical summaries of efforts to understand the CD38 molecule and to develop monoclonal antibodies that target it. We focus particularly on efforts involving multiple myeloma, a malignancy of terminally differentiated B cells that remains incurable despite many advances. An era of anti-CD38 monoclonal antibody therapy for myeloma is approaching, one that hopefully will enable patients to live longer a...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

Importance of Histological Verification of Positive Positron Emission Tomography /Computed Tomography Findings in the Follow-up of Patients with Malignant Lymphoma
This study emphasizes that the histological diagnosis should be confirmed in post-therapy PET/CT-positive patients via biopsy before adjusting the treatment regimen due to the high false-positive rate including unexpected SPM or benign/normal tissue lesions. Teaser We evaluated histologically-verified post-therapy PET-positive lesions in the follow-up of 190 patients with malignant lymphoma in the first complete remission. Among 32 histologically-verified patients, 10 exhibited relapse of lymphoma, 11 were second primary malignancies and 11 were benign/normal lesions. The symptomatic PET-positive patients had a significant...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated with High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
Conclusion Even in an era of novel therapies, cytogenetically identified high-risk myeloma patients have worse prognoses than standard-risk myeloma patients after auto-HCT, and having > one high-risk cytogenetic abnormality further reduces survival. Teaser We retrospectively compared the outcomes of autologous hematopoietic stem cell transplantation (auto-HCT) among 670 multiple myeloma (MM) patients stratified as high-risk and standard-risk based on cytogenetic and FISH abnormalities. High-risk MM patients have shorter survival than standard-risk MM patients. Having > one high-risk cytogenetic abnormality an...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

Trends and Disparities in Cardiovascular Mortality among Survivors of Hodgkin Lymphoma
Conclusions Despite an overall decrease in CVM in HL survivors over the last decades, older patients, black patients and males, especially those who have advanced stage at diagnosis are at the highest risk of cardiovascular death. Cardiovascular screening and risk modification should be intensified in HL patients with these characteristics. Teaser This is a study that investigates trends and disparities among patients with Hodgkin lymphoma. Using the SEER database, we show that the incidence of cardiovascular mortality has been decreasing over the past two decades. We also show that black race, male gender, older age at di...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

Outcomes after Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma with Bulky Disease
Conclusion Stage IIB bulky HL patients had excellent outcomes after combined-modality therapy. Treatment strategies have changed substantially over time, with concomitant improvements in disease outcomes and long-term toxicities. Teaser Treatment for stage II bulky Hodgkin lymphoma with B symptoms is controversial, with patients treated using either early-stage or advanced disease treatment paradigms, varying greatly by institution. We reviewed patients with stage IIB bulky disease at our institution treated primarily with combined-modality therapy and found that these patients had generally excellent outcomes when treated...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

The impact of alemtuzumab therapy and route of administration in T-prolymphocytic leukemia (T-PLL): A single center experience
Conclusion In this large series of T-PLL patients treated at a single tertiary care center, we confirmed the prior observation of superiority of intravenous alemtuzumab over other therapies. HSCT was feasible in a minority of potentially eligible patients. Early transplant referral should be considered for all eligible patients. Teaser T-PLL is a rare neoplasm with available data restricted to small prospective trials and retrospective case series. In a consecutive cohort of 41 patients, we confirm that intravenous alemtuzumab is associated with survival advantage over other therapies including subcutaneous alemtuzumab. HS...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

Treatment of patients with myelodysplastic syndrome (MDS) with lenalidomide in clinical routine in Austria
Publication date: Available online 5 August 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): G. Aschauer, R. Greil, W. Linkesch, T. Nösslinger, R. Stauder, S. Burgstaller, M. Fiegl, M. Fridrik, M. Girschikofsky, F. Keil, A.L. Petzer Lenalidomide has demonstrated remarkable efficacy for therapy of lower-risk myelodysplastic syndromes (MDS) associated with 5q-. The present evaluation aims to describe the characteristics and outcomes of low-risk MDS patients treated with lenalidomide in Austria. For this retrospective, multicentre, observational analysis of MDS patients who received lenalidomide...
Source: Clinical Lymphoma Myeloma and Leukemia - August 6, 2015 Category: Cancer & Oncology Source Type: research

Outcomes of treatment in Slovene follicular lymphoma patients
Conclusions The outcomes in our routinely treated FL patients confirm the benefit of adding rituximab to chemotherapy and are comparable to the results of pivotal clinical studies. The outcome of our FL patients was improved in terms of both PFS and OS. Teaser The treatment outcomes of follicular lymphoma (FL) patients have been positively influenced by the introduction of rituximab in the last two decades. A retrospective analysis of progression-free survival and overall survival of 278 routinely treated Slovene FL patients confirmed the significant benefit of adding rituximab to chemotherapy and into maintenance setting ...
Source: Clinical Lymphoma Myeloma and Leukemia - August 4, 2015 Category: Cancer & Oncology Source Type: research

Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients
Conclusion IDH1 and IDH2 mutations are negative prognostic markers in AML patients. A novel mutation (R132V) was detected in IDH1 in our cohort of AML patients. We recommend molecular testing for IDH1 and IDH2 mutations for proper risk stratification of AML patients before the start of therapy. Micro-Abstract This study aimed to determine the frequencies and clinical impact of isocitrate dehydrogenase (IDH) 1 and IDH2 mutations among Egyptian acute myeloid leukemia (AML) patients. The exon 4 of IDH1 and IDH2 were sequenced for detection of mutations in 211 AML bone marrow samples. The IDH1 and IDH2 mutations were detected...
Source: Clinical Lymphoma Myeloma and Leukemia - July 18, 2015 Category: Cancer & Oncology Source Type: research

Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience
Conclusion t-CMML comprises a small portion of all CMML cases (11%). Median OS in the dn-CMML group was longer than in the t-CMML group but LT seemed to be similar in terms of incidence and time to occurrence. Additional studies are needed to confirm our results. Micro-Abstract Treatment-related (t-) chronic myelomonocytic leukemia (CMML) carry a worse clinical outcome than de novo (dn-) CMML (dn-CMML). Most t-CMML patients had received previous chemotherapy exposure. Patients with t-CMML had a shorter median overall survival than those with dn-CMML but similar time to leukemic transformation. Patients with t-CMML have a ...
Source: Clinical Lymphoma Myeloma and Leukemia - July 18, 2015 Category: Cancer & Oncology Source Type: research

Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper
This article reports recommendations on the use of BV issued during a consensus project, sponsored by the Italian Society of Hematology (SIE) and its affiliate societies, Società Italiana di Ematologia Sperimentale (SIES) and Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Scientific evidence on BV was evaluated by a panel of experts, and consensus was developed by group discussion for key questions selected according to the clinical relevance. The following key issues were addressed: testing CD30 positivity to assess eligibility to BV; assessing practice indications of BV in Hodgkin lymphoma and systemic a...
Source: Clinical Lymphoma Myeloma and Leukemia - July 18, 2015 Category: Cancer & Oncology Source Type: research

PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab
Publication date: Available online 19 June 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ameen A. Salahudeen, Arjun Gupta, Jeremy C. Jones, Robert W. Cowan, Madhuri Vusirikala, Chi Kwong, Harris V.K. Naina (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 18, 2015 Category: Cancer & Oncology Source Type: research

Infection Rate and Risk Factors in Patients Treated with Azacitidine
Publication date: Available online 17 July 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): M. Orero, C. Villegas, S. Ortiz, K.P. Javier, S. Costa, P.L. Pérez, M. Roig, M. Linares (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 18, 2015 Category: Cancer & Oncology Source Type: research

BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Conclusion BEAM seemed to be associated with higher toxicity with comparable efficacy to HDM ASCT. Longer follow-up is needed to determine whether there is any significant difference in PFS between the 2 groups. Micro-Abstract We report a retrospective study comparing BEAM (BCNU, etoposide, cytarabine, and melphalan) conditioning (n = 24) versus high-dose melphalan (HDM) (n = 19) for patients with myeloma receiving salvage autologous stem cell transplantation (ASCT) whose disease progressed after a first ASCT with HDM. BEAM seemed to be associated with higher toxicity with comparable efficacy to ASCT with HDM. Longer foll...
Source: Clinical Lymphoma Myeloma and Leukemia - July 11, 2015 Category: Cancer & Oncology Source Type: research

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
Conclusion POM + LoDEX offer good clinical outcomes that lead to improved and prolonged HRQoL compared with HiDEX in patients with RRMM and end-stage disease. Micro-Abstract As part of study MM-003 (A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone vs. High-Dose Dexamethasone in Patients With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study [NIMBUS]), we examined changes in health-related quality of life (HRQoL) in 433 patients with relapsed/refractory multiple myeloma (RRMM) ran...
Source: Clinical Lymphoma Myeloma and Leukemia - July 4, 2015 Category: Cancer & Oncology Source Type: research

Addition of GM-CSF to Fludarabine-containing Regimens in Chronic Lymphocytic Leukemia and Indolent non-Hodgkin Lymphoma
Conclusion GM-CSF-based chemo-immunotherapy was well-tolerated and resulted in a high response rate and warrants evaluation if larger studies. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 4, 2015 Category: Cancer & Oncology Source Type: research